Using USP i and USP IV for discriminating dissolution rates of nano- and microparticle-loaded pharmaceutical strip-films

AAPS PharmSciTech

Volumn 13, Issue 4, 2012, Pages 1473-1482

  Sievens Figueroa, Lucas ^a,d   Pandya, Natasha ^a   Bhakay, Anagha ^a   Keyvan, Golshid ^b   Michniak Kohn, Bozena ^c   Bilgili, Ecevit ^a   Davé, Rajesh N ^a  

^a NEW JERSEY INSTITUTE OF TECHNOLOGY   (United States)

^b The State University of New Jersey   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

BCS class II; dissolution; drug nanoparticles; flow through cell; pharmaceutical strip films

Indexed keywords

DODECYL SULFATE SODIUM; GLYCEROL; GRISEOFULVIN; NANOPARTICLE;

ARTICLE; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SOLUBILITY; FLOW RATE; IN VITRO STUDY; PARTICLE SIZE; PHARMACEUTICAL STRIP FILMF; PRIORITY JOURNAL;

CHEMISTRY, PHARMACEUTICAL; DOSAGE FORMS; GRISEOFULVIN; MEMBRANES, ARTIFICIAL; NANOPARTICLES; PARTICLE SIZE; SODIUM DODECYL SULFATE; SOLUBILITY; WATER;

EID: 84871652747     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-012-9875-3     Document Type: Article

References (46)

1. Krishnaiah YSR. Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. J Bioequiv Availab. 2010;2:28-36. doi: 10.4172/jbb.1000027.
2. Kesisoglou F, Panmai S, Wu Y. Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59(7):631-44. doi: 10.1016/j.addr.2007.05.003.
3. Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev. 2011;63(6):427-40. doi: 10.1016/j.addr.2010.12.007.
4. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995;125(1):91-7. doi: 10.1016/0378-5173(95)00122-Y.
5. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3-19. doi: 10.1016/S0169-409X(00) 00118-6.
6. Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm. 2006;62(1):3-16. doi: 10.1016/j.ejpb.2005.05.009.
7. Xiaohui P, Jin S, Mo L, Zhonggui H. Formulation of nanosuspensions as a new approach for the delivery of poorly soluble drugs. Curr Nanosci. 2009;5(4):417-27. doi: 10.2174/157341309789378177.
8. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-20.
9. de Villiers MM. Influence of agglomeration of cohesive particles on the dissolution behaviour of furosemide powder. Int J Pharm. 1996;136:175-9.
10. de Villiers MM. Description of the kinetics of the deagglomeration of drug particle agglomerates during powder mixing. Int J Pharm. 1997;151:1-6.
11. Otto DP, de Villiers MM. Physicochemical principles of nanosized drug delivery systems. In: de Villiers MM, Aramwit P, Kwon GS, editors. Nanotechnology in drug delivery. New York: Springer; 2009. p. 4-5.
12. Heng D, Ogawa K, Cutler DJ, Chan H-K, Raper JA, Ye L, et al. Pure drug nanoparticles in tablets: what are the dissolution limitations? J Nanoparticle Res. 2010;12(5):1743-54.
13. Finholt. Influence of formulation on dissolution rate. In: Leeson LJ, Carstensen JT editors. Dissolution Technology, The Industrial Pharmaceutical Technology Section of the Academy of Pharmaceutical science, Washington, 1974, pp. 106-46.
14. Hu J, Johnston KP, Williams III RO. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind Pharm. 2004;30(3):233-45.
15. Bhakay A, Merwade M, Bilgili E, Dave RN. Novel aspects of wet milling for the production of microsuspensions and nanosuspensions of poorly water-soluble drugs. Drug Dev Ind Pharm. 2011;37(8):963-76. doi: 10.3109/03639045.2010.551775.
16. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci. 2003;18(2):113-20.
17. Shafiq-un-Nab S, Shakeel F, Talegaonkar S, Ali J, Baboota S, Ahuja A. Formulation development and optimization using nanoemulsion technique: a technical note. AAPS Pharm Sci Tech. 2007;8(2):28-34.
18. Rogers TL, Gillespie IB, Hitt JE, Fransen KL, Crowl CA, Tucker CJ, et al. Development and characterization of a scalable controlled precipitation process to enhance the dissolution of poorly water-soluble drugs. Pharm Res. 2004;21:3990-4005. doi: 10.1023/B:PHAM.0000048196.61887.e5.
19. Browne DC, Kieselmann S. Low-level drug release-rate testing of ocular implants using USP apparatus 4 dissolution and HPLC end analysis. Diss Tech. 2010;17(1):12-4.
20. Bhardwaj U, Burgess DJ. A novel USP apparatus 4 based release testing method for dispersed systems. Int J Pharm. 2010;388:287-94. doi: 10.1016/j.ijpharm.2010.01.009.
21. Neubert A, Sternberg K, Nagel S, Harder C, Schmitz KP, Kroemer HK. Development of a vessel-simulating flow-through cell method for the in vitro evaluation of release and distribution from drug-eluting stents. J Control Release. 2008;130:2-8. doi: 10.1208/s12249-010-9548-z.
22. Zhang GH, Vadino WA, Yang TT, Cho WP, Chaudry IA. Evaluation of the flow-through cell dissolution apparatus: effects of flow rate, glass beads and tablet position on drug release from different type of tablets. Drug Dev Ind Pharm. 1994;20(13):2063-78.
23. Gjellan K, Graffner C. Comparative dissolution studies of rectal formulations using the basket, the paddle and the flow-through methods: II. Ibuprofen in suppositories of both hydrophilic and lipophilic types. Int J Pharm. 1994;112(3):233-40. doi: 10.1016/0378-5173(94)90359-X.
24. Perng CY, Kearney AS, Palepu NR, Smith BR, Azzarano LM. Assessment of oral bioavailability enhancing approaches for SB-247083 using flow-through cell dissolution testing as one of the screens. Int J Pharm. 2003;250(1):147-56. doi: 10.1016/S0378-5173(02)00521-5.
25. Nicklasson M, Orbe A, Lindberg J, Borga B, Magnusson AB, Nilsson G, et al. A collaborative study of the in vitro dissolution of phenacetin crystals comparing the flow through method with the USP Paddle method. Int J Pharm. 1991;69(3):255-64. doi: 10.1016/0378-5173(91)90367-W.
26. Rawat A, Burgess DJ. USP apparatus 4 method for in vitro release testing of protein loaded microspheres. Int J Pharm. 2011;409(1-2):178-84. doi: 10.1016/j.ijpharm.2011.02.057.
27. Nicklasson M, Wennergren B, Lindberg J, Persson C, Ahlgren R, Palm B. A collaborative in vitro dissolution study using the flow-through method. Int J Pharm. 1987;37:195-202.
28. Gjellan K, Magnusson AB, Ahlgren R, Callmer K, Christensen DF, Espmarker U, et al. A collaborative study of the in vitro dissolution of acetylsalicylic acid gastro-resistant capsules comparing the flow-through cell method with the USP paddle method. Int J Pharm. 1997;151(1):81-90. doi: 10.1016/S0378-5173(97) 04891-6.
29. Wennergren L, Lindberg L, Nicklasson M, Nilsson G, Nyberg G, Ahlgren R. A collaborative in vitro dissolution study: comparing the flow-through method with the USP paddle method using USP prednisone calibrator tablets. Int J Pharm. 1989;53:35-41.
30. Bhattachar S, Wesley J, Fioritto A, Martin P, Babu S. Dissolution testing of a poorly soluble compound using the flow-through cell dissolution apparatus. Int J Pharm. 2002;236:135-43.
31. Heng D, Cutler D, Chan H, Yun J, Raper J. What is a suitable dissolution method for drug nanoparticles? Pharm Res. 2008;25(7):1696-701. doi: 10.1007/s11095-008-9560-0.
32. Dixit RP, Puthli SP. Oral strip technology: overview and future potential. J Control Release. 2009;139:94-107. doi: 10.1016/j.jconrel.2009.06. 014.
33. Shimoda H, Taniguchi K, Nishimura M, Matsuura K, Tsukioka T, Yamashita H. Preparation of a fast dissolving oral thin film containing dexamethasone: a possible application to antiemesisduring cancer chemotherapy. Eur J Pharm Biopharm. 2009;73:361-5. doi: 10.1016/j.ejpb.2009.08.010.
34. Garsuch V, Breitkreutz J. Comparative investigations on different polymers for the preparation of fast-dissolving oral films. J Pharm Pharmacol. 2010;62(4):539-45. doi: 10.1211/jpp/62.04.0018.
35. Bess W, Kulkarni N, Ambike S, Ramsay M, inventors. McNeil-PPC, Inc., assignee. Fast dissolving orally consumable films containing a taste masking agent. Us Patent 7,648,712. 19 Jan 2010.
36. Sievens-Figueroa L, Bhakay A, Jerez-Rozo J, Pandya N, Romañach R, Michniak-Kohn B, et al. Preparation and characterization of hydroxypropyl methyl cellulose films containing stable BCS class II drug nanoparticles for pharmaceutical applications. Int J Pharm. 2012;423(2):496-508. doi: 10.1016/j.ijpharm.2011.12.001.
37. The United States Pharmacopeia. US Pharmacopeia (USP 35-NF 30).
38. Rao VM, Lin M, Larive CK, Southard MZ. A mechanistic study of griseofulvin dissolution into surfactant solutions under laminar flow conditions. J Pharm Sci. 1997;86(10):1132-7.
39. Kakhi M. Classification of the flow regimes in the flow-through cell. Eur J Pharm Sci. 2009;37(5):531-44. doi: 10.1016/j.ejps.2009.04.003.
40. Liu Y, Sun C, Hao Y, Jiang T, Zheng L, Wang S. J Pharm Pharmaceut Sci. 2010;13(4):589-606.
41. Kakran M, Sahoo NG, Li L, Judeh Z, Wang Y, Chong K, et al. Int J Pharm. 2010;383:285-92.
42. Monteiro A, Afolabi A, Bilgili E. Continuous Production of drug nanoparticle suspensions via wet stirred media milling: a fresh look at the rehbinder effect. Drug Dev. Ind. Pharm. 2012. doi: 10.3109/03639045.2012.676048)
43. D'Arcy DM, Corrigan OI, Healy AM. Evaluation of hydrodynamics in the basket dissolution apparatus using computational fluid dynamics-dissolution rate implications. Eur J Pharm Sci. 2006;27:259-67.
44. D'Arcy D, Liu B, Bradley G, Healy A, Corrigan O. Hydrodynamic and species transfer simulations in the USP 4 dissolution apparatus: Considerations for dissolution in a low velocity pulsing flow. Pharm Res. 2010;27(2):246-58.
45. Wang Y, Armenante PM. A novel off-center paddle impeller (OPI) dissolution testing system for reproducible dissolution testing of solid dosage forms. J Pharm Sci. 2012;101(2):746-60.
46. Bai G, Armenante PM. Hydrodynamic, mass transfer, and dissolution effects induced by tablet location during dissolution testing. J Pharm Sci. 2009;98(4):1511-31.